托珠单抗辅助传统改善病情抗风湿药治疗类风湿关节炎的疗效与安全性

Efficacy and safety of tocilizumab assisted with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis

目的分析托珠单抗辅助传统改善病情抗风湿药(DMARDs)治疗类风湿关节炎(RA)的疗效与安全性。方法将于我院就诊的132例RA患者按随机数字表法分为观察组(66例,托珠单抗+DMARDs)与对照组(66例,DMARDs)。比较两组的治疗效果。结果观察组的治疗总有效率为93.94%,高于对照组的74.24%(P<0.05)。治疗后,两组ESR、CRP、RF水平均降低,且观察组低于对照组(P<0.05);两组Th17/Treg、IL-1β、IL-6、IL-17、TNF-α水平均降低,且观察组低于对照组(P<0.05);两组MST、VAS评分、压痛关节数、肿胀关节数及HAQ评分均改善,且观察组优于对照组(P<0.05);两组不良反应总发生率无明显差异(P>0.05)。结论托珠单抗辅助DMARDs治疗RA不仅能够更好地改善临床症状和患者的生活质量,还可提高临床疗效。

Objective To analyze the efficacy and safety of tocilizumab assisted with disease modifying anti-rheumatic drugs(DMARDs) in the treatment of rheumatoid arthritis(RA). Methods A total of 132 cases with RA treated in our hospital were divided into observation group(66 cases, tocilizumab+DMARDs) and control group(66 cases, DMARDs) by random number table method. The therapeutic effects of the two groups were compared. Results The total effective rate of treatment in the observation group was 93.94%, which was higher than 74.24% in the control group(P <0.05). After treatment, the levels of ESR, CRP and RF in the two groups decreased, and those in the observation group were lower than the control group(P<0.05);the levels of Th17/Treg, IL-1β, IL-6, IL-17 and TNF-α in the two groups decreased,and those in the observation group were lower than the control group(P<0.05);the MST, scores of VAS, numbers of joint tenderness, numbers of joint swelling and scores of HAQ in the two groups improved, and those in the observation group were better than the control group(P <0.05). There was no significant difference in the total incidences of adverse reactions between the two groups(P>0.05). Conclusion Tocilizumab assisted with DMARDs in the treatment of RA can not only better improve the clinical symptoms and quality of life of patients, but also improve clinical efficacy.